Pathway,Count
Beta2-Glycoprotein I plasma levels,8
"1,5-anhydroglucitol levels",9
AIDS progression,16
Abdominal aortic aneurysm,20
Ability to confide in someone,22
Accelerated cognitive decline after conversion of MCI to Alzheimer's disease,10
Accelerometer-based physical activity measurement (average acceleration),6
Acne (severe),223
Activated partial thromboplastin time,36
Acute graft versus host disease in bone marrow transplantation (recipient effect),10
Acute insulin response,10
Acute lymphoblastic leukemia (B-cell precursor),7
Acute lymphoblastic leukemia (childhood),38
Acute lymphoblastic leukemia in childhood (B cell precursor),9
Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced),7
Acylcarnitine levels,10
Adiponectin levels,30
Adiposity,8
Adolescent idiopathic scoliosis,23
Adult asthma,21
Advanced age-related macular degeneration,61
Advanced glycation end-product levels,9
Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs),6
Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs),6
Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs),12
Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs),6
Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors),5
Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin),9
Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin),7
Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel),7
Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin),5
Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine),5
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin),7
Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel),8
Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule),6
Adverse response to chemotherapy in breast cancer (alopecia) (FDC/DC),8
Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel),5
Adverse response to lamotrigine and phenytoin,12
Adverse response to radiation therapy,6
Age at first birth,27
Age at smoking initiation in chronic obstructive pulmonary disease,10
Age at voice drop,24
Age-related cataracts,7
Age-related cataracts (age at onset),7
Age-related hearing impairment,21
Age-related macular degeneration,67
Age-related macular degeneration (choroidal neovascularisation),7
Age-related macular degeneration (extreme sampling),11
Age-related macular degeneration (geographic atrophy),10
Age-related nuclear cataracts,11
Aggressive periodontitis,6
Aggressiveness in attention deficit hyperactivity disorder,18
Aging,16
Aging (time to event),8
Aging traits,5
Airflow obstruction,31
Airway imaging phenotypes,13
Airway responsiveness in chronic obstructive pulmonary disease,13
Airway wall thickness,14
ALT levels after remission induction therapy in actute lymphoblastic leukemia (ALL),48
Alanine transaminase levels,38
Albumin-globulin ratio,60
Alcohol and nicotine co-dependence,13
Alcohol consumption,22
Alcohol consumption (drinkers vs non-drinkers),6
Alcohol consumption (maxi-drinks),16
Alcohol consumption in current drinkers,7
Alcohol dependence,55
Alcohol dependence symptom count,19
Alcohol use disorder (consumption score),8
Alcohol use disorder (dependence and problematic use scores),5
Alcohol use disorder (total score),46
Alcoholic chronic pancreatitis,145
"Allergic disease (asthma, hay fever or eczema)",172
Allergic rhinitis,114
Allergic sensitization,44
Allergy,37
Alopecia areata,94
Aluminium levels,25
Alzheimer disease and age of onset,25
Alzheimer's disease,48
Alzheimer's disease (APOE e4 interaction),8
Alzheimer's disease (age of onset),18
Alzheimer's disease (cognitive decline),50
Alzheimer's disease (late onset),64
Alzheimer's disease (survival time),8
Alzheimer's disease biomarkers,25
Alzheimer's disease in APOE e4+ carriers,21
Alzheimer's disease in APOE e4- carriers,44
Alzheimer's disease progression score,12
Amino acid levels,9
Amyloid A serum levels,5
Amyotrophic lateral sclerosis,54
Amyotrophic lateral sclerosis (C9orf72 mutation interaction),5
Amyotrophic lateral sclerosis (age of onset),10
Amyotrophic lateral sclerosis (sporadic),182
Amyotrophic lateral sclerosis in C9orf72 mutation negative individuals,5
Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals,5
Anger,25
Angiotensin-converting enzyme inhibitor intolerance,44
Ankylosing spondylitis,47
Anorexia nervosa,47
Anthropometric traits,10
Anti-saccade response,38
Antibody level in response to infection,8
Anticoagulant levels,8
Antineutrophil cytoplasmic antibody-associated vasculitis,25
Anxiety disorder,9
Anxiety in major depressive disorder,8
Aortic root size,26
Apolipoprotein A1 levels,5
Appendicular lean mass,5
Arthritis (juvenile idiopathic),8
Asparaginase hypersensitivity in acute lymphoblastic leukemia,9
Asparaginase-induced acute pancreatitis in acute lymphoblastic leukemia (onset time),11
Aspartate aminotransferase levels,37
Asperger disorder,6
Asthma,204
Asthma (bronchodilator response),6
Asthma (childhood onset),52
Asthma (moderate or severe),27
Asthma (sex interaction),7
Asthma and hay fever,22
Asthma exacerbations in inhaled corticosteroid treatment,14
Atopic dermatitis,67
Atopic march,15
Atrial fibrillation,240
Atrioventricular conduction,7
Attention deficit hyperactivity disorder,90
Attention deficit hyperactivity disorder and conduct disorder,31
Attention deficit hyperactivity disorder or cannabis use,7
Attention deficit hyperactivity disorder symptom score,9
Attention function in attention deficit hyperactive disorder,23
Autism,16
Autism spectrum disorder,5
Autism spectrum disorder or schizophrenia,752
"Autism spectrum disorder, ADHD, bipolar disorder, MDD, and schizophrenia (combined)",47
Autoimmune thyroid diseases (Graves disease or Hashimoto's thyroiditis),13
Axial length,64
"B-cell malignancies (CLL, Hodgkin lymphoma or multiple myeloma) (pleiotropy)",16
BMI (adjusted for smoking behaviour),77
BMI in non-smokers,58
BMI in smokers,18
BRCA1/2-negative high-risk breast cancer,16
Bacteremia,7
Barrett's esophagus,13
Barrett's esophagus  or Esophageal adenocarcinoma,20
Barrett's esophagus x pack-years of smoking exposure interaction,5
Basal cell carcinoma,47
Basophil percentage of granulocytes,51
Basophil percentage of white cells,50
Beard thickness,36
Behcet's disease,15
Beta thalassemia/hemoglobin E disease,8
Beta-2 microglubulin plasma levels,7
Bilirubin levels,31
Binge eating behaviour and bipolar disorder,5
Biochemical measures,13
Biomedical quantitative traits,7
Bipolar disorder,194
Bipolar disorder (age of onset <21) or attention deficit hyperactivity disorder,6
Bipolar disorder (body mass index interaction),12
Bipolar disorder (inflammation and infection response interaction),13
Bipolar disorder and eating disorder,7
Bipolar disorder and schizophrenia,32
Bipolar disorder lithium response (categorical) or schizophrenia,8
Bipolar disorder lithium response (continuous) or schizophrenia,9
Bipolar disorder or attention deficit hyperactivity disorder,11
Bipolar disorder or major depressive disorder,9
Bipolar disorder with mood-incongruent psychosis,17
Birdshot chorioretinopathy,5
Birth length,7
Birth weight,72
Black vs. blond hair color,6
Black vs. red hair color,6
Bladder cancer,28
Bladder cancer (smoking interaction),9
Blond vs non-blond hair color,6
Blond vs. brown hair color,5
Blond vs. brown/black hair color,160
Blood and toenail selenium levels,12
Blood metabolite levels,158
Blood metabolite ratios,50
Blood osmolality (transformed sodium),20
Blood pressure,98
Blood pressure (smoking interaction),33
Blood pressure measurement (high sodium and potassium intervention),6
Blood pressure measurement (high sodium intervention),6
Blood pressure measurement (low sodium intervention),6
Blood pressure traits (multi-trait analysis),10
Blood protein levels,2091
Blood sugar levels,23
Blood trace element (Cu levels),15
Blood trace element (Se levels),14
Blood trace element (Zn levels),19
Blood urea nitrogen levels,57
Body fat percentage,23
Body mass index,1246
Body mass index  (smoking years interaction),6
Body mass index (SNP x SNP interaction),10
Body mass index (adult),18
Body mass index (age <50),53
Body mass index (age>50),69
Body mass index (alcohol intake interaction),5
Body mass index (change over time),14
Body mass index (change over time) in chronic obstructive pulmonary disease,6
Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease,5
Body mass index (joint analysis main effects and physical activity interaction),91
Body mass index (joint analysis main effects and smoking interaction),77
Body mass index (recreational physical activity interaction),5
Body mass index and waist-hip ratio (pleiotropy),8
Body mass index in asthmatics,7
Body mass index in physically active individuals,80
Body mass index in physically inactive individuals,24
Body mass index x age interaction,40
Body mass index x sex x age interaction (4df test),109
Bone fracture in osteoporosis,9
Bone mineral density,89
Bone mineral density (Ward's triangle area),18
Bone mineral density (femoral neck),9
Bone mineral density (femoral neck) in inflammatory bowel disease,5
Bone mineral density (hip),54
"Bone mineral density (paediatric, lower limb)",9
"Bone mineral density (paediatric, skull)",16
"Bone mineral density (paediatric, total body less head)",15
"Bone mineral density (paediatric, upper limb)",8
Bone mineral density (spine),35
Bone mineral density (spine) and age at menarche,6
Bone mineral density (total hip),31
Bone properties (heel),11
Bone ultrasound measurement (broadband ultrasound attenuation),23
Bone ultrasound measurement (velocity of sound),15
Borderline personality disorder,20
Bortezomib-induced peripheral neuropathy in multiple myeloma,5
Brain connectivity,7
Brain imaging,10
Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction),8
Brain structure,17
Brain volume in infants (grey matter),12
Brain volume in infants (white matter),6
Branched-chain amino acid levels (Isoleucine),5
Breast Cancer in BRCA1 mutation carriers,8
Breast cancer,219
Breast cancer (early onset),5
Breast cancer (estrogen-receptor negative),30
Breast cancer (prognosis),5
Breast cancer (survival),25
Breast cancer and/or colorectal cancer,15
Breast milk fatty acid composition (infant genotype effect),6
Breast milk fatty acid composition (maternal genotype effect),7
Breast size,93
Breastfeeding duration,14
Bronchial hyperresponsiveness in asthma,7
Bronchopulmonary dysplasia,39
Bronchopulmonary dysplasia in preterm infants,8
Brown vs. black hair color,36
Brown vs. non-brown hair color,7
Bulimia nervosa,30
C-reactive protein,29
C-reactive protein (red blood cell fatty acid level interaction),7
C-reactive protein levels,30
C-reactive protein levels or HDL-cholesterol levels (pleiotropy),20
C-reactive protein levels or LDL-cholesterol levels (pleiotropy),22
C-reactive protein levels or total cholesterol levels (pleiotropy),20
C-reactive protein levels or triglyceride levels (pleiotropy),22
CSF tryptophan concentration in tuberculous meningitis,10
Cadmium levels,46
Caffeine consumption,14
Caffeine metabolism (plasma caffeine) level),5
"Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) level)",6
Caffeine metabolism (plasma paraxanthine caffeine ratio),12
"Caffeine metabolism (plasma 3,7-dimethylxanthine (theobromine) level)",6
Calcium levels,61
Callous-unemotional behaviour,5
Cancer,26
Cancer (pleiotropy),16
Cannabis dependence,5
Cannabis dependence symptom count,12
Cannabis use,11
Cannabis use (initiation),8
Capecitabine sensitivity,8
Carboplatin disposition in epthelial ovarian cancer,26
Cardiac Troponin-T levels,19
Cardiac hypertrophy,23
Cardiac repolarization,6
Cardiac structure and function,6
Cardiometabolic and hematological traits,18
Cardiovascular disease risk factors,20
Cardiovascular risk factors (age interaction),9
Carotid atherosclerosis in HIV infection,7
Carotid intima media thickness,20
Carotid plaque burden,40
Carotid plaque burden (smoking interaction),6
Celiac disease,130
Celiac disease or Rheumatoid arthritis,14
Central corneal thickness,66
Cerebellum growth,6
Cerebral amyloid deposition (PET imaging),41
Cerebral amyloid deposition in APOEe4 non-carriers (PET imaging),36
Cerebral amyloid deposition positivity (PET imaging),5
Cerebral cortical growth,7
Cerebrospinal AB1-42 levels in Alzheimer's disease dementia,21
Cerebrospinal AB1-42 levels in mild cognitive impairment,19
Cerebrospinal AB1-42 levels in normal cognition,74
Cerebrospinal P-tau181p levels,48
Cerebrospinal T-tau levels,44
Cerebrospinal fluid AB1-42 levels,60
Cerebrospinal fluid beta-site APP cleaving enzyme levels,9
Cerebrospinal fluid clusterin levels,24
Cerebrospinal fluid levels of Alzheimer's disease-related proteins,18
Cerebrospinal fluid p-Tau181p:AB1-42 ratio,9
Cerebrospinal fluid p-tau levels,24
Cerebrospinal fluid p-tau levels in Alzheimer's disease dementia,10
Cerebrospinal fluid p-tau levels in mild cognitive impairment,26
Cerebrospinal fluid p-tau levels in normal cognition,7
Cerebrospinal fluid t-tau levels,27
Cerebrospinal fluid t-tau levels in Alzheimer's disease dementia,9
Cerebrospinal fluid t-tau levels in mild cognitive impairment,17
Cerebrospinal fluid t-tau levels in normal cognition,24
Cerebrospinal fluid t-tau:AB1-42 ratio,43
Cervical artery dissection,5
Cervical cancer,31
Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer,5
Change in glucose in response to thiazide diuretic treatment in hypertension,6
Chemerin levels,7
Childhood and early adolescence aggressive behavior,7
Childhood body mass index,24
Childhood ear infection,41
Childhood steroid-sensitive nephrotic syndrome,7
Chin dimples,74
Chlamydia trachomatis seropositivity,6
Chloride levels,24
Cholangiocarcinoma in primary sclerosing cholangitis,10
Cholangiocarcinoma in primary sclerosing cholangitis (time to event),16
Cholesterol efflux capacity,7
Cholesterol efflux capacity (ABCA-1 dependent assay),10
Cholesterol efflux capacity (cAMP stimulated assay),5
Cholesterol ester levels in large LDL,5
Cholesterol ester levels in medium LDL,5
"Cholesterol, total",121
Chromium levels,32
Chronic back pain,5
Chronic bronchitis and chronic obstructive pulmonary disease,12
Chronic central serous retinopathy,8
Chronic hepatitis B infection,15
Chronic hepatitis C infection,9
Chronic inflammatory diseases (pleiotropy),177
Chronic kidney disease,81
Chronic lymphocytic leukemia,74
Chronic mucus hypersecretion,6
Chronic myeloid leukemia,9
Chronic obstructive pulmonary disease,47
Chronic obstructive pulmonary disease (moderate to severe),9
Chronic obstructive pulmonary disease (severe),6
Chronic obstructive pulmonary disease-related biomarkers,36
Chronic periodontitis (mean interproximal clinical attachment level),9
Chronic venous disease,12
Chronotype,31
Cingulate cortical amyloid beta load,5
Circulating fibroblast growth factor 23 levels,28
Circulating myeloperoxidase levels (plasma),8
Circulating myeloperoxidase levels (serum),8
Circulating phylloquinone levels,5
Circulating vasoactive peptide levels,5
Cisplatin-induced ototoxicity,6
Cleft lip with or without cleft palate,20
Cleft lip with or without cleft palate (maternal periconceptional vitamin use interaction),12
Cleft palate,5
Clinical laboratory measurements,7
Clopidogrel active metabolite levels,8
Clozapine-induced agranulocytosis,73
Clozapine-induced agranulocytosis/granulocytopenia in treatment-resistant schizophrenia,27
Clozapine-induced cytotoxicity,9
Coagulation factor levels,10
Cobalt levels,28
Cocaine dependence,8
Coenzyme Q10 levels,9
Coffee consumption,28
Coffee consumption (cups per day),18
Cognitive ability,58
Cognitive ability (MTAG),81
Cognitive decline (age-related),43
Cognitive decline rate in late mild cognitive impairment,126
Cognitive flexibility,5
Cognitive function,92
Cognitive performance,116
Cognitive test performance,6
Cold medicine-related SJS/TEN with severe ocular complications,6
Cold sores,10
Colorectal cancer,124
Colorectal cancer (calcium intake interaction),5
Colorectal cancer (diet interaction),21
Colorectal or endometrial cancer,29
Common carotid intima-media thickness,14
Common carotid intima-media thickness in HIV infection,19
Common carotid intima-media thickness in HIV negative individuals,15
Complement C3 and C4 levels,10
Conduct disorder,5
Conduct disorder (maternal expressed emotions interaction),7
Conduct disorder (symptom count),6
Congenital heart disease (inherited effect),5
Congenital heart disease (maternal effect),12
Congenital left-sided heart lesions,8
Conotruncal heart defects,11
Conotruncal heart defects (inherited effects),5
Conotruncal heart defects (maternal effects),11
Contrast sensitivity,23
Copper levels,67
Corneal astigmatism,63
Corneal curvature,14
Corneal structure,38
Coronary artery aneurysm in Kawasaki disease,26
Coronary artery calcification,55
Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes,38
Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes,32
Coronary artery calcified atherosclerotic plaque score in type 2 diabetes,25
Coronary artery disease,433
"Coronary artery disease (myocardial infarction, PTCA, CABG, angina or CIHD)",94
Coronary artery disease in type 1 diabetes,19
Coronary artery disease or ischemic stroke,19
Coronary artery disease or large artery stroke,24
Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction),5
Coronary heart disease,77
Coronary heart disease (SNP X SNP interaction),5
Corrected insulin response,6
Corrected insulin response adjusted for insulin sensitivity index,6
Cortical amyloid beta load,11
Corticobasal degeneration,5
Cortisol levels (saliva),10
Cotinine glucuronidation,16
Cough in response to angiotensin-converting enzyme inhibitor drugs,17
Craniofacial microsomia,58
Creatine kinase levels,48
Creatinine levels,97
Crohn's disease,613
Crohn's disease (time to surgery),6
Crohn's disease-related phenotypes,5
Current cigarettes per day in chronic obstructive pulmonary disease,8
Cutaneous lupus erythematosus,11
Cutaneous malignant melanoma,22
Cutaneous psoriasis,11
Cutaneous squamous cell carcinoma,14
Cystic fibrosis severity,7
Cytomegalovirus antibody response,6
D-dimer levels,15
DNA methylation (parent-of-origin),8
DNA methylation (variation),21
Daytime sleep phenotypes,263
Decline in glucose metabolism in posterior cingulate cortex,7
Deep ovarian and/or rectovaginal disease with dense adhesions,10
Dehydroepiandrosterone sulphate levels,11
Delirium,50
Delta-5 desaturase activity response to n3-polyunsaturated fat supplement,6
Dementia and core Alzheimer's disease neuropathologic changes,15
Dementia with Lewy bodies,5
Dental caries,75
Dentate gyrus granule cell layer volume,11
Dentate gyrus molecular layer volume,12
Depression,69
Depression (quantitative trait),11
Depression and alcohol dependence,6
Depression in smokers,54
Depressive and manic episodes in bipolar disorder,7
Depressive episodes in bipolar disorder,7
Depressive symptoms (SSRI exposure interaction),10
Dermatomyositis,5
Dermatomyositis or juvenile dermatomyositis,6
Diabetes in response to antihypertensive drug treatment (treatment strategy interaction),5
Diabetic kidney disease,24
Diabetic retinopathy,47
Diabetic retinopathy in type 2 diabetes,5
Dialysis-related mortality,32
Diastolic blood pressure,646
Diastolic blood pressure (cigarette smoking interaction),57
Diastolic blood pressure night-to-day ratio in hypertension,5
Diastolic blood pressure response to hydrochlorothiazide in hypertension,10
Diastolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),42
Diastolic blood pressure x alcohol consumption interaction (2df test),96
Diastolic blood pressure x smoking status (current vs non-current) interaction (1df test),18
Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test),109
Diastolic blood pressure x smoking status (ever vs never) interaction (1df test),5
Diastolic blood pressure x smoking status (ever vs never) interaction (2df test),94
Dietary macronutrient intake,9
Differentiated thyroid cancer,10
Diffuse cutaneous systemic sclerosis,9
Diffuse large B cell lymphoma,8
Diffusing capacity of the lung for carbon monoxide traits,6
Digit length ratio,15
Digit length ratio (left hand),14
Digit length ratio (right hand),13
Diisocyanate-induced asthma,261
Dimensional psychopathology (Arousal),20
Dimensional psychopathology (Cognitive),12
Dimensional psychopathology (Negative),10
Dimensional psychopathology (Positive),8
Dimensional psychopathology (Social),14
Disc degeneration (lumbar),9
Discordance in emotional problems in monozygotic twins,5
Disease progression in age-related macular degeneration,97
Disease progression to choroidal neovascularization form in age-related macular degeneration,5
Disrupted circadian rhythm (low relative amplitude of rest-activity cycles),8
Diverticular disease,156
Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer,7
Drinking behavior,5
Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN),8
Drug-induced liver injury (flucloxacillin),7
Dupuytren's disease,56
Dysmenorrheic pain,13
Dysmenorrheic pain severity,7
EGFR mutation-positive lung adenocarcinoma,6
Ear morphology,9
Early onset atrial fibrillation,6
Early-onset Parkinson's disease,14
Eating disorders,20
Eating disorders (purging via substances),16
Echocardiographic traits,5
Economic and political preferences,9
Economic and political preferences (time),7
Educational attainment,71
Educational attainment (years of education),9
Egg allergy,6
Egg allergy (maternal genetic effects),6
Egg allergy (parent-of-origin effect),5
Electrocardiographic conduction measures,6
Electrocardiographic traits,23
Electrodermal activity,5
Electroencephalogram traits,16
Electroencephalographic traits in alcoholism,5
Elevated fasting plasma glucose,5
Elevated serum carcinoembryonic antigen levels,11
Empathy quotient,21
Emphysema distribution in smoking,8
Emphysema imaging phenotypes,36
Emphysema-related traits,7
End-stage coagulation,9
End-stage renal disease,7
Endometrial cancer,45
Endometrial cancer (Non-endometrioid histology),7
Endometrial cancer (endometrioid histology),39
Endometrial endometrioid carcinoma,10
Endometriosis,49
Energy expenditure (24h),12
Entorhinal cortical thickness,5
Eosinophil counts,199
Eosinophil percentage of granulocytes,152
Eosinophil percentage of white cells,160
Eosinophilic esophagitis,15
Epilepsy,8
Epilepsy and lamotrigine-induced maculopapular eruptions,28
Epithelial ovarian cancer,26
Epstein-Barr virus copy number in lymphoblastoid cell lines,57
Epstein-Barr virus immune response (EBNA-1),10
Erectile dysfunction,46
Erectile dysfunction and prostate cancer treatment,23
Erectile dysfunction in type 1 diabetes,6
Erosive tooth wear (severe vs non-severe),40
Erosive tooth wear (severe vs none or mild),26
Erythema nodosum in inflammatory bowel disease,11
Erythrocyte cadmium concentration,5
Erythrocyte cadmium concentration in never smokers,10
Erythrocyte sedimentation rate,5
Esophageal adenocarcinoma,12
Esophageal adenocarcinoma x gastroesophageal reflux disease interaction,5
Esophageal cancer,15
Esophageal cancer (squamous cell),7
Esophageal squamous cell carcinoma,16
Essential tremor,5
Estradiol levels,8
Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer,13
Event free survival in diffuse large B-cell lymphoma treated with immunochemotherapy,6
Ewing sarcoma,12
Excessive daytime sleepiness,14
Excessive hairiness,9
Exhaled carbon monoxide levels in smokers with chronic obstructive pulmonary disease,7
Exhaled nitric oxide levels,7
Exhaled nitric oxide output,7
Experiencing mood swings,38
Exploratory eye movement dysfunction in schizophrenia (cognitive search score),15
Exploratory eye movement dysfunction in schizophrenia (responsive search score),7
Extraversion,5
Extremely high intelligence,78
Exudative age-related macular degeneration,7
Eye color,12
Eye color traits,6
Eye morphology,13
Eyebrow thickness,80
F-cell distribution,11
Facial emotion recognition,5
Facial emotion recognition (sad faces),25
Facial morphology,9
Facial pigmentation,7
Factor VII,9
Familial lung adenocarcinoma,18
Familial lung cancer,10
Familial squamous cell lung carcinoma,43
Fast beta electroencephalogram,10
Fasting blood glucose,39
Fasting blood glucose (BMI interaction),31
Fasting blood insulin,11
Fasting blood insulin (BMI interaction),21
Fasting insulin (dietary factor interaction),24
Fasting plasma glucose,27
Fat distribution (HIV),17
Febrile seizures,5
Febrile seizures (MMR vaccine-related),8
Feeling fed-up,29
Feeling guilty,20
Feeling hurt,25
Feeling lonely,6
Feeling miserable,34
Feeling nervous,37
Feeling tense,19
Feeling worry,43
Femoral neck bone mineral density,45
Fibrinogen,40
Fibrinogen levels,68
Folate pathway vitamin levels,10
Follicular lymphoma,13
Food addiction,12
Food allergy,18
Food allergy (maternal genetic effects),8
Food allergy (parent-of-origin effect),8
Food antigen IgG levels,9
Forced expiratory volume in 1 second (occupational environmental exposures interaction),7
Forehead morphology,9
Formal thought disorder in schizophrenia,5
Fractional excretion of metabolites in chronic kidney disease,6
Fractional exhaled nitric oxide (childhood),17
Fractional shortening,6
Fractures,29
Freckles,12
Free cholesterol levels in large LDL,5
Free thyroxine concentration,21
Frontotemporal dementia,19
Frontotemporal dementia (age at onset),8
Frontotemporal dementia with GRN mutation,12
Frontotemporal dementia with GRN mutation (age at onset),6
Fuchs's corneal dystrophy,8
"Functional impairment in major depressive disorder, bipolar disorder and schizophrenia",8
GIP levels in response to oral glucose tolerance test (120 minutes),12
GLP-1 levels in response to oral glucose tolerance test (fasting),5
Gait speed in old age,14
Gallstone disease,30
Gambling,13
Gamma glutamyl transferase levels,59
Gamma glutamyl transpeptidase,7
Gastric adenocarcinoma (histologically verified),6
Gastric cancer,12
Gastroesophageal reflux disease,12
General cognitive ability,299
Generalized epilepsy,15
Gestational age at birth (maternal effect),36
Giant cell arteritis,9
Glaucoma,52
Glaucoma (primary angle closure),12
Glaucoma (primary open-angle),76
Glioblastoma,16
Glioblastoma (age-stratified),6
Glioma,25
Global electrical heterogeneity phenotypes,18
Glomerular filtration rate,111
Glomerular filtration rate (creatinine),81
Glomerular filtration rate (cystatin C),5
Glomerular filtration rate change in heart transplantation,5
Glomerular filtration rate in chronic kidney disease,30
Glomerular filtration rate in non diabetics (creatinine),37
Glucocorticoid-induced osteonecrosis,9
Glucocorticoid-induced osteonecrosis (age 10 years and older),11
Glucose homeostasis traits,70
Glycated hemoglobin levels,66
Glycemic traits,6
Glycemic traits (pregnancy),14
Glycerophospholipid levels,15
Gout,49
Granulocyte count,133
Granulocyte percentage of myeloid white cells,159
Graves' disease,38
Gut microbiota (bacterial taxa),67
Gut microbiota (beta diversity),21
Gut microbiota (functional units),56
HDL Cholesterol - Triglycerides (HDLC-TG),8
HDL cholesterol,238
HDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,5
HDL cholesterol levels,93
HIV-1 control,19
HIV-1 susceptibility,27
HIV-1 viral setpoint,37
Hair color,61
Hair greying,36
Hair morphology,15
Hair shape,11
Hand grip strength,156
Headache,26
Hearing function,13
Heart failure,17
Heart rate,36
Heart rate increase in response to exercise,18
Heart rate response to exercise,21
Heart rate response to recovery post exercise,19
Heart rate response to recovery post exercise (10 sec),22
Heart rate response to recovery post exercise (20 sec),25
Heart rate response to recovery post exercise (30 sec),22
Heart rate response to recovery post exercise (40 sec),23
Heart rate response to recovery post exercise (50 sec),27
Heart rate variability traits (RMSSD),13
Heart rate variability traits (SDNN),14
Heart rate variability traits (pvRSA/HF),8
Heel bone mineral density,898
Height,527
Helicobacter pylori serologic status,7
Helping behaviour (self reported),7
Hematocrit,153
Hematological and biochemical traits,33
Hematological parameters,13
Hematology traits,27
Hemoglobin,33
Hemoglobin A1c levels,37
Hemoglobin concentration,128
Hemoglobin levels,34
Hemostatic factors and hematological phenotypes,22
Hepatitis B,9
Hepatitis B surface antigen seroclearance in chronic hepatitis B infection,6
Hepatitis B vaccine response,7
Hepatitis C induced liver fibrosis,6
Hepatocellular carcinoma,14
Hepatocellular carcinoma in hepatitis B infection,5
Hepcidin levels,9
Hepcidin/ferritin ratio,34
Hepcidin/transferrin saturation ratio,10
Heschl's gyrus morphology,38
High altitude adaptation,9
High density lipoprotein cholesterol levels,71
High light scatter reticulocyte count,172
High light scatter reticulocyte percentage of red cells,172
Hip circumference,69
Hip circumference adjusted for BMI,99
Hip geometry,7
Hip minimal joint space width,10
Hip shape (DXA scan),6
Hippocampal atrophy,32
Hippocampal sclerosis,8
Hippocampal subfield CA1 volume,10
Hippocampal subfield CA3 volume,9
Hippocampal subfield CA4 volume,11
Hippocampal tail volume,11
Hippocampal tail volume (corrected for total hippocampal volume),8
Hippocampal volume,56
Hippocampal volume in Alzheimer's disease dementia,61
Hippocampal volume in mild cognitive impairment,16
Hippocampal volume in normal cognition,7
Hirschsprung disease,15
Hodgkin's lymphoma,29
Homeostasis model assessment of beta-cell function,11
Homeostasis model assessment of beta-cell function (dietary factor interaction),21
Homeostasis model assessment of insulin resistance (dietary factor interaction),25
Homocysteine levels,14
Household income,6
Huntington's disease progression,47
Hyperactive-impulsive symptoms,6
Hyperopia,6
Hypersomnia (HLA-DQB1*06:02 negative),7
Hypertension,61
Hypertension (SNP x SNP interaction),8
Hyperthyroidism,11
Hypertriglyceridemia,41
Hypospadias,24
Hypothyroidism,75
Idiopathic dilated cardiomyopathy,69
Idiopathic inflammatory myopathy,8
Idiopathic intracranial hypertension,9
Idiopathic membranous nephropathy,15
Idiopathic osteonecrosis of the femoral head,10
Idiopathic pulmonary fibrosis,18
IgA nephropathy,36
IgE grass sensitization,10
IgE levels,18
IgG N-glycosylation phenotypes (multivariate analysis),12
IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis),8
IgG digalactosylation phenotypes (multivariate analysis),9
IgG disialylation phenotypes (multivariate analysis),7
IgG fucosylation phenotypes (multivariate analysis),10
IgG galactosylation phenotypes (multivariate analysis),13
IgG glycosylation,23
IgG monogalactosylation phenotypes (multivariate analysis),9
IgG sialylation phenotypes (multivariate analysis),10
Immature fraction of reticulocytes,125
Immune reponse to smallpox (secreted IFN-alpha),34
Immune reponse to smallpox (secreted IL-10),6
Immune reponse to smallpox (secreted IL-12p40),11
Immune reponse to smallpox (secreted IL-1beta),14
Immune reponse to smallpox (secreted IL-2),18
Immune reponse to smallpox (secreted TNF-alpha),8
Immune response to anthrax vaccine,14
Immune response to measles-mumps-rubella vaccine,18
Immune response to smallpox vaccine (IL-6),47
Immunoglobulin A,20
Immunoglobulin A vasculitis,9
Immunoglobulin light chain (AL) amyloidosis,14
Immunoglobulin measurement (zinc sulfate turbidity test),5
Incident atrial fibrillation,5
Infant length,15
Inflammatory biomarkers,25
Inflammatory bowel disease,709
Inflammatory bowel disease (early onset),11
Inflammatory skin disease,93
Influenza A (H1N1) infection,18
Influenza A (H1N1) severity,7
Information processing speed,28
Initial alcohol sensitivity,34
Initial pursuit acceleration,51
Initial pursuit acceleration in psychotic disorders,19
Insomnia,35
Insomnia (caffeine-induced),9
Insulin resistance/response,11
Insulin-like growth factors,8
Insulin-related traits,5
Intelligence,59
Intelligence (MTAG),366
Interferon alpha levels in systemic lupus erythematosus,18
Interleukin-1-receptor antagonist levels,12
Interleukin-10 levels,16
Interleukin-6 levels,21
Interstitial lung disease,10
Intracranial aneurysm,47
Intracranial volume,7
"Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy)",6
Intraocular pressure,401
Intrinsic epigenetic age acceleration,7
Iris characteristics,5
Iris color (L* coordinate),8
Iris color (a* coordinate),5
Iris color (b* coordinate),6
Iron status biomarkers,23
Iron status biomarkers (ferritin levels),21
Iron status biomarkers (iron levels),21
Iron status biomarkers (total iron binding capacity),40
Iron status biomarkers (transferrin levels),9
Iron status biomarkers (transferrin saturation),39
Irritable bowel syndrome,24
Irritable mood,33
Ischemic stroke,67
Ischemic stroke (cardioembolic),12
Ischemic stroke (large artery atherosclerosis),14
Ischemic stroke (small-vessel),12
Isovolumetric relaxation time,5
Itch intensity from mosquito bite,64
Itch intensity from mosquito bite adjusted by bite size,117
JT interval (sulfonylurea treatment interaction),18
Joint mobility (Beighton score),35
Juvenile idiopathic arthritis (oligoarticular or rheumatoid factor-negative polyarticular),37
Kawasaki disease,21
Kidney function decline traits,11
Knee osteoarthritis,27
L-arginine levels,6
LDL cholesterol,181
LDL cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,8
LDL cholesterol levels,64
LDL peak particle diameter (total fat intake interaction),11
Lactate dehydrogenase levels,12
Language performance in older adults (adjusted for episodic memory),8
Large HDL particle concentration,9
Large LDL particle concentration,5
Large artery stroke,7
Laryngeal squamous cell carcinoma,10
Late-onset Alzheimer's disease,46
Late-onset myasthenia gravis,15
Lateral ventricular volume in normal aging,11
Laterality in neovascular age-related macular degeneration,7
Lead levels,45
Lead levels in blood,18
Lean body mass,7
Left superior temporal gyrus thickness (schizophrenia interaction),6
Left ventricular internal dimension in diastole,5
Left ventricular internal dimension in systole,6
Left ventricular obstructive tract defect (inherited effect),9
Left ventricular obstructive tract defect (maternal effect),5
Leisure-time exercise behaviour,7
Leisure-time exercise behaviour (age-stratified),6
Length of menstrual cycle,9
Lentiform nucleus volume,8
Leprosy,28
Lewy body disease,13
Lifespan,8
Lifetime average cigarettes per day in chronic obstructive pulmonary disease,7
Light vs. dark hair color,7
Limited cutaneous systemic scleroderma,20
Lipid metabolism phenotypes,37
Lipid traits,23
Lipid traits (pleiotropy) (HIPO component 1),20
Lipoprotein (a) - cholesterol levels,7
Lipoprotein (a) levels,42
Lipoprotein phospholipase A2 activity in cardiovascular disease,13
Lipoprotein-associated phospholipase A2 activity and mass,14
Lipoprotein-associated phospholipase A2 activity change in response to statin therapy,7
Liver enzyme levels,19
Liver enzyme levels (alanine transaminase),17
Liver enzyme levels (alkaline phosphatase),24
Liver enzyme levels (aspartate transaminase),8
Liver enzyme levels (gamma-glutamyl transferase),41
Liver fibrosis in pediatric non-alcoholic fatty acid liver disease,5
Liver transplant-free survival in primary sclerosing cholangitis (time to event),9
Lobe attachment (rater scored),10
Lobe attachment (rater-scored or self-reported),9
Lobe size,6
Local histogram emphysema pattern,10
Logical memory (delayed recall),24
Logical memory (delayed recall) in Alzheimer's disease dementia,6
Logical memory (delayed recall) in mild cognitive impairment,19
Logical memory (delayed recall) in normal cognition,67
Logical memory (immediate recall),23
Logical memory (immediate recall) in Alzheimer's disease dementia,10
Logical memory (immediate recall) in mild cognitive impairment,18
Logical memory (immediate recall) in normal cognition,36
Loneliness,104
Loneliness (MTAG),71
Loneliness (linear analysis),28
Loneliness (multivariate analysis),33
Longevity,74
Longevity (90 years and older),10
Longitudinal alcohol consumption,6
Longitudinal change in brain amyloid plaque burden,5
Low density lipoprotein cholesterol levels,44
Low high density lipoprotein cholesterol levels,11
Low tan response,24
Low vWF levels,10
Lower body strength,8
Lumbar spine bone mineral density,36
Lumbar spine bone mineral density (integral),24
Lumbar spine bone mineral density (trabecular),16
Lung adenocarcinoma,123
Lung cancer,225
Lung cancer (smoking interaction),5
Lung cancer in ever smokers,153
Lung cancer in never smokers,34
Lung disease severity in cystic fibrosis,9
Lung function (FEV1),67
Lung function (FEV1/FVC),81
Lung function (FVC),67
Lung function (forced vital capacity),7
Lupus nephritis in systemic lupus erythematosus,26
Lymphocyte counts,174
Lymphocyte percentage of white cells,129
Lymphoma,13
MGMT methylation in smokers,7
Macular telangiectasia type 2,7
Macular thickness,191
Magnesium levels,13
Major depressive disorder,212
Major depressive disorder (broad),8
Malaria,6
Male fertility,6
Male infertility,5
Male-pattern baldness,251
Mammographic density (dense area),14
Manganese levels,58
Manic episodes in bipolar disorder,5
Matrix metalloproteinase-8 levels,9
Mean arterial pressure,110
Mean arterial pressure (alcohol consumption interaction),8
Mean arterial pressure (long-term average),5
Mean arterial pressure x alcohol consumption (light vs heavy) interaction (2df test),44
Mean arterial pressure x alcohol consumption interaction (2df test),81
Mean corpuscular hemoglobin,336
Mean corpuscular hemoglobin concentration,133
Mean corpuscular volume,365
Mean diameter of HDL particles,6
Mean platelet volume,281
Medium LDL particle concentration,5
Melanoma,43
Memory dysfunction in frontotemporal lobe dementia,6
Menarche (age at onset),212
Menarche and menopause (age at onset),7
Menopause (age at onset),94
Menstruation quality of life impact (dysmenorrhea),6
Mercury levels,35
Metabolic syndrome,45
Metabolic syndrome (bivariate traits),9
Metabolic syndrome (multivariate analysis),7
Metabolic traits,46
Metabolite levels,111
Metabolite levels  (X-11787),29
Metabolite levels (5-HIAA),12
Metabolite levels (5-HIAA/ MHPG Ratio),9
Metabolite levels (Dihydroxy docosatrienoic acid),20
Metabolite levels (HVA),12
Metabolite levels (HVA-5-HIAA Factor score),8
Metabolite levels (HVA/5-HIAA ratio),9
Metabolite levels (HVA/MHPG ratio),23
Metabolite levels (MHPG),13
Metabolite levels (Pyroglutamine),23
Metabolite levels (lipid measures),8
Metabolite levels (lipoprotein measures),27
Metabolite levels (small molecules and protein measures),39
Methadone dose in opioid dependence,37
Methotrexate phramacokinetics (acute lymphoblastic leukemia),5
Microalbuminuria,30
Middle childhood and early adolescence aggressive behavior,7
Midgestational circulating levels of PBDEs,6
Midgestational circulating levels of PBDEs (fetal genetic effect),10
Midgestational circulating levels of PCBs,15
Migraine,74
Migraine - clinic-based,10
Migraine without aura,18
Mild influenza (H1N1) infection,43
Milk allergy,8
Mitochondrial DNA levels,22
Mitral valve prolapse,16
Moderate or severe diarrhoea in darapladib-treated cardiovascular disease (time to event),5
Moderate to vigorous physical activity levels,14
Modified Stumvoll Insulin Sensitivity Index (BMI interaction),12
Molar-incisor hypomineralization,9
Molybdenum levels,26
Monobrow,76
Monobrow thickness,25
Monoclonal gammopathy of undetermined significance,29
Monocyte chemoattractant protein-1 levels,5
Monocyte count,224
Monocyte early outgrowth colony forming units,5
Monocyte percentage of white cells,171
Mood instability,14
Morning vs. evening chronotype,42
Mortality in heart failure,11
Mortality in sepsis,22
Mosquito bite size,95
Motion sickness,32
Moyamoya disease,15
Multiple keratinocyte cancers,5
Multiple myeloma,30
Multiple myeloma and monoclonal gammopathy,13
Multiple sclerosis,244
Multiple sclerosis (OCB status),13
Multiple sclerosis (age of onset),8
Multiple sclerosis (severity),12
Multiple sclerosis and HDL levels (pleiotropy),7
Multiple sclerosis and triglyceride levels (pleiotropy),6
Multiple sclerosis--Brain Glutamate Levels,5
Multiple system atrophy,23
Multiple system atrophy (pathologically confirmed),16
Mumps,5
Myasthenia gravis,6
Myeloid white cell count,140
Myeloproliferative neoplasms,5
Myocardial infarction,59
Myocardial infarction (early onset),14
Myopia,70
Myopia (pathological),42
Myositis,14
N-glycan levels,10
Narcolepsy,21
Narcolepsy with cataplexy,7
Nasopharyngeal carcinoma,20
Nasopharyngeal carcinoma (SNP x SNP interaction),77
Neonatal cytokine/chemokine levels (fetal genetic effect),15
Neonatal lupus,10
Nephrolithiasis,8
Nephropathy,20
Neuritic plaque,11
Neuritic plaques or neurofibrillary tangles (pleiotropy),5
Neuritic plaques or neurofibrillary tangles or cerebral amyloid angiopathy (pleiotropy),5
Neuroblastoma,8
Neurociticism,97
Neurocognitive impairment in HIV-1 infection (continuous),5
Neurocognitive impairment in HIV-1 infection (dichotomous),7
Neurofibrillary tangles,14
Neuromyelitis optica,7
Neuromyelitis optica (AQP4-IgG-positive),7
Neuropathic pain in type 2 diabetes,6
Neuroticism,142
Neutrophil count,187
Neutrophil count in HIV-infection,6
Neutrophil percentage of granulocytes,148
Neutrophil percentage of white cells,113
Nickel levels,40
Nicotine dependence,22
Nicotine dependence and major depression (severity of comorbidity),25
Night sleep phenotypes,555
Nodular sclerosis Hodgkin lymphoma,10
Non-albumin protein levels,68
Non-alcoholic fatty liver disease histology (lobular),8
Non-alcoholic fatty liver disease histology (other),11
Non-cardia gastric cancer,7
Non-glioblastoma glioma,22
Non-melanoma skin cancer,23
Non-obstructive azoospermia,6
Non-response to antidepressants and depression,7
Non-response to bupropion and depression,7
Non-response to citalopram or escitalopram and depression,8
Non-response to selective serotonin reuptake inhibitors and depression,8
Non-small cell lung cancer,16
Nonalcoholic fatty liver disease,13
Nonsyndromic cleft lip with cleft palate,33
Nonsyndromic cleft lip with or without cleft palate,13
Normalized brain volume,5
Nose morphology,24
Nose size,39
Number of children ever born,7
Obese vs. thin,15
Obesity,55
Obesity (early onset extreme),21
Obesity (extreme),29
Obesity in adult survivors of childhood cancer exposed to cranial radiation,5
Obesity-related traits,804
Objective response to lithium treatment,13
Obsessive-compulsive disorder,19
Obsessive-compulsive disorder or autism spectrum disorder,10
Obsessive-compulsive symptoms,18
Obstetric antiphospholipid syndrome,14
Obstructive sleep apnea during REM sleep (apnea hypopnea index),6
Obstructive sleep apnea trait (apnea hypopnea index),24
Obstructive sleep apnea trait (average respiratory event duration),12
Oleic acid (18:1n-9) levels,18
Opioid sensitivity,5
Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder,24
Optic cup area,30
Optic disc area,26
Optic disc parameters,5
Optic nerve measurement (cup area),9
Optic nerve measurement (cup-to-disc ratio),11
Optic nerve measurement (disc area),7
Optic nerve measurement (rim area),6
Oral cavity and pharyngeal cancer,12
Oral cavity cancer,13
Orofacial clefts,32
Oropharynx cancer,11
Orthostatic hypotension,5
Ossification of the posterior longitudinal ligament of the spine,12
Osteoarthritis,12
Osteoarthritis (hip),23
Osteoarthritis biomarkers,8
Osteoporosis-related phenotypes,8
Osteoprotegerin levels,14
Osteosarcoma,6
Otitis media,6
Otitis media (chronic),6
Otitis media (recurrent),6
Ovarian cancer,68
Ovarian reserve,7
Overweight status,6
P wave duration,17
P wave terminal force,8
PCA3 expression level,5
PR interval,67
PR interval in Tripanosoma cruzi seropositivity,15
PR segment,12
Paclitaxel disposition in epithelial ovarian cancer,47
Paclitaxel-induced neuropathy,15
Paget's disease,10
Pain medicine use during menstruation,6
Palmitic acid (16:0) levels,16
Palmitoleic acid (16:1n-7) levels,26
Pancreatic cancer,130
Pancreatic ductal adenocarcinoma,15
Pancreatitis,6
Paneth cell defects in Crohn's disease,9
Panic disorder,10
Papillary thyroid cancer,9
Parent of origin effect on language impairment (paternal),11
Parental lifespan,6
Parental longevity (both parents in top 10 percent),8
Parental longevity (combined parental age at death),11
"Parental longevity (combined parental attained age, Martingale residuals)",32
Parental longevity (father's age at death),8
Parental longevity (father's attained age),23
Parental longevity (mother's attained age),10
Parkinson disease and lewy body pathology,10
Parkinson's disease,184
Parkinson's disease (age of onset),6
Parkinson's disease (motor and cognition),5
Partial epilepsies,8
Peak cortisol response to low dose short synacthen test in corticosteroid treated asthma,6
Peak insulin response,12
Peanut allergy,18
Peanut allergy (maternal genetic effects),6
Peanut allergy (parent-of-origin effect),6
Pediatric autoimmune diseases,45
Pediatric bone mineral content (radius),5
Pediatric non-alcoholic fatty liver disease activity score,7
Pelvic organ prolapse,33
Pelvic organ prolapse (moderate/severe),47
Perceived unattractiveness to mosquitoes,26
Percent mammographic density,6
Percentage gas trapping,15
Periodontal disease-related phenotypes,38
Periodontal microbiota,34
Periodontitis,14
Periodontitis (CDC/AAP),26
Periodontitis (DPAL),14
Periodontitis (Mean PAL),35
Periodontitis (PAL4Q3),15
Perioperative myocardial infarction in coronary artery bypass surgery,7
Peripheral arterial disease (traffic-related air pollution interaction),12
Peripheral artery disease,11
Personality dimensions,15
Personality traits in bipolar disorder,6
Phospholipid levels (plasma),27
Phospholipid levels in large HDL,10
Phospholipid levels in medium HDL,7
Phosphorus levels,21
Photic sneeze reflex,65
Physical activity (overall physical activity time),7
Pit-and-Fissure caries,15
Placental abruption,8
Plantar warts,10
Plasma amyloid beta peptide concentrations (ABx-40),9
Plasma amyloid beta peptide concentrations (ABx-42),7
Plasma androstenedione levels in resected early stage-receptor positive breast cancer,7
Plasma clusterin levels,15
Plasma factor VII activating protease levels,6
Plasma homocysteine levels (post-methionine load test),5
Plasma kynurenine levels in major depressive disorder,6
Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid),18
Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid),10
Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid),21
Plasma omega-6 polyunsaturated fatty acid levels (adrenic acid),17
Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid),23
Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid),23
Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid),26
Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid),28
Plasma parathyroid hormone levels,21
Plasma plasminogen activator levels,5
Plasma PCSK9 levels in stable coronary artery disease,14
Plasma renin activity levels,7
Plasma thyroid-stimulating hormone levels,7
Plasma trimethylamine N-oxide levels,6
Plasminogen activator inhibitor type 1 levels (PAI-1),10
Platelet aggregation,14
Platelet count,366
Platelet distribution width,170
Plateletcrit,231
Pneumococcal bacteremia,7
Pneumoconiosis in silica exposure,6
Pneumonia,8
Polycystic ovary syndrome,47
Polymyositis,12
Poor prognosis in Crohn's disease,5
Possible neuropathic pain in post total joint replacement surgery for osteoarthritis,6
Post bronchodilator FEV1,126
Post bronchodilator FEV1 in COPD,40
Post bronchodilator FEV1/FVC ratio,206
Post bronchodilator FEV1/FVC ratio in COPD,53
Post bronchodilator FEV1/FVC ratio in smoking,8
Post bronchodilator percent predicted FEV1 in smoking,8
Post-traumatic stress disorder,20
Post-traumatic stress disorder (asjusted for relatedness),15
Posterior cortical atrophy and Alzheimer's disease,5
Potassium levels,18
Pre bronchodilator FEV1/FVC ratio,5
Preeclampsia,18
Premature menopause in childhood cancer survivors,5
Presence of antiphospholipid antibodies,24
Preterm birth (maternal effect),12
Prevalent atrial fibrillation,12
Primary biliary cholangitis,112
Primary biliary cirrhosis,47
Primary sclerosing cholangitis,36
Primary tooth development (number of teeth),20
Primary tooth development (time to first tooth eruption),20
Problematic alcohol use in trauma-exposed individuals,5
Progranulin levels,6
Progressive supranuclear palsy,16
Proinsulin levels,11
Prostate cancer,399
Prostate cancer (SNP x SNP interaction),74
Prostate cancer (advanced),15
Prostate cancer (early onset),15
Prostate-specific antigen levels,43
Prostate-specific antigen levels (conditioned on lead SNPs),9
Protein C levels,11
Protein quantitative trait loci,52
Proteinuria and chronic kidney disease,11
Proteinuria in chronic kidney disease,6
Prothrombin time,13
Prudent dietary pattern,47
Psoriasis,127
Psoriasis vulgaris,46
Psoriatic arthritis,24
Psychosis (atypical),15
Psychosis and Alzheimer's disease,11
Psychosis in Alzheimer's disease,7
Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale),6
Psychosis proneness (hypomanic personality scale and revised social anhedonia scale),5
Psychosis proneness (hypomanic personality scale),6
Pubertal anthropometrics,30
Pulmonary arterial hypertension,5
Pulmonary artery enlargement and chronic obstructive pulmonary disease,5
Pulmonary function,61
Pulmonary function (smoking interaction),54
Pulmonary function decline,16
Pulmonary function in asthmatics,7
Pulse pressure,567
Pulse pressure x alcohol consumption (light vs heavy) interaction (2df test),19
Pulse pressure x alcohol consumption interaction (2df test),56
Pursuit maintenance gain,99
Pursuit maintenance gain in psychotic disorders,11
Putamen volume,9
Pyoderma gangrenosum in inflammatory bowel disease,22
QRS complex (12-leadsum),11
QRS complex (Cornell),7
QRS duration,55
QRS interval (sulfonylurea treatment interaction),17
QT interval,117
QT interval (ambient particulate matter interaction),7
QT interval (drug interaction),17
QT interval (sulfonylurea treatment interaction),13
Quantitative traits,29
RR interval (heart rate),11
Radiation response,11
Rapid functional decline in sporadic amyotrophic lateral sclerosis,9
Reaction time,65
Reading and spelling,6
Reading disability or specific language impairment (pleiotropy),13
Reading disability or specific language impairment adjusted for IQ (pleiotropy),12
Recalcitrant atopic dermatitis,5
Recurrent major depressive disorder,9
Red blood cell count,246
Red blood cell density in sickle cell anemia,9
Red blood cell fatty acid levels,17
Red blood cell traits,82
Red cell distribution width,230
Red vs. brown/black hair color,20
Refractive astigmatism,57
Refractive error,30
Regular attendance at a gym or sports club,41
Regular attendance at a pub or social club,53
Regular attendance at a religious group,89
Relative hand skill in reading disability,24
Remission after SSRI treatment in MDD or neuroticism,7
Remission after SSRI treatment in MDD or openness,6
Renal cell carcinoma,18
Renal function-related traits (BUN),20
Renal function-related traits (eGRFcrea),12
Renal function-related traits (sCR),10
Renal overload gout,5
Renal sinus fat,8
Renal underexcretion gout,9
Residual cognition,6
Resistance to Mycobacterium tuberculosis in HIV+ individuals measured by a negative TST (continuous),5
Resistant hypertension,6
Resistin levels,5
Response to SSRI (symptom remission),14
Response to SSRI in MDD or openness,6
Response to TNF antagonist treatment,8
Response to TNF inhibitor in rheumatoid arthritis (change in swollen 28-joint count),17
Response to TNF inhibitor in rheumatoid arthritis (change in tender 28-joint count),12
Response to TNF-alpha inhibitors in rheumatoid arthritis,8
Response to Vitamin E supplementation,14
Response to acetaminophen (hepatotoxicity),5
Response to alcohol consumption (flushing response),11
Response to amphetamines,31
Response to angiotensin II receptor blocker therapy,20
Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy),5
Response to anti-TNF therapy in rheumatoid arthritis,13
Response to anti-depressant treatment in major depressive disorder,13
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 (Grade 1 peripheral neuropathy),9
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 (Grade 2 peripheral neuropathy),12
Response to anti-retroviral therapy (ddI/d4T) in HIV-1 (Grade 3 peripheral neuropathy),12
Response to antidepressants,5
Response to antidepressants (symptom improvement),31
Response to antidepressants (symptom remission),12
Response to antidepressants and depression,7
Response to antidepressants in depression,11
Response to antineoplastic agents,5
Response to antipsychotic therapy (extrapyramidal side effects),7
Response to antipsychotic treatment,25
Response to antipsychotic treatment in schizophrenia,7
Response to antipsychotic treatment in schizophrenia (reasoning),9
Response to antipsychotic treatment in schizophrenia (working memory),9
Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1),38
Response to bupropion and depression,8
Response to bupropion in depression,7
Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab),6
Response to citalopram or escitalopram and depression,6
Response to citalopram or escitalopram in depression,10
Response to citalopram treatment,11
Response to cognitive-behavioural therapy in anxiety disorder,22
Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis,22
Response to cytadine analogues (cytosine arabinoside),16
Response to cytidine analogues (gemcitabine),9
Response to exercise (triglyceride level interaction),5
Response to fenofibrate,7
Response to fenofibrate (HDL cholesterol levels),23
Response to fenofibrate (LDL cholesterol levels),21
Response to fenofibrate (adiponectin levels),18
Response to fenofibrate (total cholesterol levels),26
Response to fenofibrate (triglyceride levels),26
Response to haloperidol in schizophrenia,6
Response to hepatitis B vaccine,20
Response to hepatitis C treatment,14
Response to iloperidone treatment (QT prolongation),6
Response to inhaled corticosteroid treatment in asthma (change in FEV1),9
Response to lithium treatment in bipolar disorder,7
Response to n-3 LC-PUFA supplementation (change in triglyceride levels),5
Response to lurasidone in schizophrenia,17
Response to mTOR inhibitor (everolimus),6
Response to mTOR inhibitor (rapamycin),6
Response to metformin (IC50),23
Response to methotrexate in juvenile idiopathic arthritis,41
Response to methylphenidate treatment in ADHD (blood pressure),5
Response to perphenazine in schizophrenia,5
Response to platinum-based agents,5
Response to platinum-based chemotherapy (carboplatin),7
Response to platinum-based chemotherapy (cisplatin),5
Response to platinum-based chemotherapy in non-small-cell lung cancer,10
Response to platinum-based neoadjuvant chemotherapy in cervical cancer,22
Response to quetiapine in schizophrenia,14
Response to radiotherapy in cancer (late toxicity),9
Response to selective serotonin reuptake inhibitors and depression,8
Response to selective serotonin reuptake inhibitors in depression,10
Response to serotonin reuptake inhibitors in major depressive disorder,21
Response to serotonin reuptake inhibitors in MDD (plasma drug and metabolite levels),18
Response to simvastatin treatment (PCSK9 protein level change),7
Response to statin therapy,102
Response to statins (LDL cholesterol change),17
Response to taxane treatment (docetaxel),15
Response to taxane treatment (placlitaxel),13
Response to tocilizumab in rheumatoid arthritis,8
Response to treatment for acute lymphoblastic leukemia,8
Response to zileuton treatment in asthma (FEV1 change interaction),12
Response to ziprazidone in schizophrenia,8
Resting heart rate,127
Resting metabolic rate,16
Resting-state electroencephalogram vigilance,42
Restless legs syndrome,39
Reticulocyte count,171
Reticulocyte fraction of red cells,180
Retinal arteriolar caliber,6
Retinal vascular caliber,18
Retinopathy in non-diabetics,11
Rhegmatogenous retinal detachment,19
Rheumatoid arthritis,182
Rheumatoid arthritis (ACPA-negative),11
Rheumatoid arthritis (ACPA-positive),74
Rheumatoid arthritis (rheumatoid factor and/or anti-CCP seropositive),5
Right lateral prefrontal cortical growth,14
Rosacea symptom severity,141
S-phenylmercapturic acid levels in smokers,11
Sarcoidosis,15
Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome),39
Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations),28
Scalp hair shape,26
Schizophrenia,882
Schizophrenia (inflammation and infection response interaction),8
Schizophrenia (treatment resistant),5
Schizophrenia or bipolar disorder,6
"Schizophrenia, bipolar disorder and depression (combined)",5
"Schizophrenia, schizoaffective disorder or bipolar disorder",5
Seasonality,10
Seasonality and depression,27
Seborrheic dermatitis,10
Sedentary behaviour duration,6
Select biomarker traits,11
Selective IgA deficiency,40
Self-rated health,15
Self-reported allergy,37
Self-reported risk-taking behaviour,33
Sense of smell,15
Sensory disturbances after bilateral sagittal split ramus osteotomy,7
Serum 25-Hydroxyvitamin D levels,8
Serum albumin level,40
Serum alkaline phosphatase levels,39
Serum bilirubin levels in metabolic syndrome,12
Serum bilirubin levels x Mediterranean diet adherence interaction in metabolic syndrome,8
Serum bilirubin levels x sex interaction in metabolic syndrome,9
Serum folate levels,17
Serum metabolite concentrations in chronic kidney disease,34
Serum metabolite levels,100
Serum metabolite ratios in chronic kidney disease,21
Serum parathyroid hormone levels,7
Serum prostate-specific antigen levels,6
Serum protein levels (sST2),8
Serum sulfate level,9
Serum thyroid-stimulating hormone levels,26
Serum total cholesterol levels,7
Serum total protein level,54
Serum urate levels in chronic kidney disease,7
Serum uric acid levels,55
Serum uric acid levels in response to allopurinol in gout,31
Severe aortic features in Marfan syndrome,9
Severe gingival inflammation,6
Severe influenza A (H1N1) infection,48
Severe malaria,19
Severe malaria (adjusted for sickle cell variant rs334),13
Severity of nausea and vomiting of pregnancy,13
Sex hormone levels,11
Sex hormone-binding globulin levels,18
Sexual dimorphism in anthropometric traits,16
Sexual dysfunction (SSRI/SNRI-related),5
Shingles,14
Sickle cell anemia (haemolysis),5
Sitting height ratio,11
Sjogren's syndrome,51
Skin aging (microtopography measurement),13
Skin colour saturation,9
Skin pigmentation,13
Skin sensitivity to sun,6
Sleep duration,56
Sleep quality,6
Sleep traits (multi-trait analysis),6
Small LDL particle concentration,6
Small cell lung carcinoma,74
Small vessel stroke,12
Smoking behavior,29
Smoking cessation in chronic obstructive pulmonary disease,8
Smoking initiation,15
Smooth-surface caries,37
Social autistic-like traits,9
Social communication problems,33
Social science traits (pleiotropy) (HIPO component 1),9
Sodium levels,19
Soluble interleukin-2 receptor subunit alpha,8
Spherical equivalent (joint analysis main effects and education interaction),25
Spherical equivalent or myopia (age of diagnosis),191
Sphingolipid levels,17
Spontaneous preterm birth (preterm birth),5
Sporadic neuroblastoma,10
Sporadic pituitary adenoma,6
Squamous cell carcinoma,23
Squamous cell lung carcinoma,139
Staphylococcus aureus infection,7
Staphylococcus aureus nasal carriage (intermittent),18
Staphylococcus aureus nasal carriage (persistent),9
Stearic acid (18:0) levels,16
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN),12
Strenuous sports or other exercises,8
Strep throat,6
Stroke,73
Stroke (ischemic),7
Subclinical trait of interstitial lung disease (basilar peel-core ratio of HAA on CT scan),10
Subcortical brain region volumes,14
Subcutaneous adipose tissue,61
Subiculum volume,9
Subjective response to lithium treatment,19
Subjective response to lithium treatment in bipolar disorder,15
Sudden cardiac arrest,29
Suffering from nerves,5
Suicide behavior,5
Suicide in bipolar disorder,7
Suicide risk,5
Sulfasalazine-induced agranulocytosis,15
Sum basophil neutrophil counts,140
Sum eosinophil basophil counts,173
Sum neutrophil eosinophil counts,133
Superior frontal gyrus grey matter volume,10
Survival in colon cancer,6
Survival in microsatellite instability low/stable colorectal cancer,5
Survival in pancreatic cancer,27
Survival in sporadic amyotrophic lateral sclerosis,5
Susceptibility to persistent hepatitis B virus infection,9
Systemic juvenile idiopathic arthritis,42
Systemic lupus erythematosus,365
Systemic lupus erythematosus and Systemic sclerosis,21
Systemic lupus erythematosus or rheumatoid arthritis,11
Systemic sclerosis,68
Systemic sclerosis (anti-centromere-positive),7
Systemic sclerosis (anti-topoisomerase-positive),8
Systolic blood pressure,657
Systolic blood pressure (alcohol consumption interaction),10
Systolic blood pressure (cigarette smoking interaction),66
Systolic blood pressure change trajectories,7
Systolic blood pressure in sickle cell anemia,14
Systolic blood pressure response to hydrochlorothiazide in hypertension,16
Systolic blood pressure x alcohol consumption (light vs heavy) interaction (2df test),44
Systolic blood pressure x alcohol consumption interaction (2df test),115
Systolic blood pressure x smoking status (current vs non-current) interaction (1df test),17
Systolic blood pressure x smoking status (current vs non-current) interaction (2df test),112
Systolic blood pressure x smoking status (ever vs never) interaction (2df test),96
TB-LM or TBLH-BMD (pleiotropy),7
Tacrolimus trough concentration in kidney transplant patients,9
Takayasu arteritis,88
Tandem gait,6
Tanning,11
Telomere length,47
Temperament,17
Temperament (bipolar disorder),10
Temporomandibular joint disorder,6
Tenofovir clearance in HIV infection,13
Testicular germ cell cancer,6
Testicular germ cell tumor,90
Thiazide-induced adverse metabolic effects in hypertensive patients,60
Thiopurine-induced alopecia in inflammatory bowel disease,11
Thiopurine-induced leukopenia in inflammatory bowel disease,5
Thrombin-activatable fibrinolysis inhibitor activation peptide,30
Thrombin-activatable fibrinolysis inhibitor levels,12
Thrombosis,15
Thyroid cancer,14
"Thyroid cancer (Papillary, radiation-related)",8
Thyroid function,5
Thyroid hormone levels,28
Thyroid peroxidase antibody levels,6
Thyroid peroxidase antibody positivity,5
Thyroid stimulating hormone,25
Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor,11
Time-dependent creatinine clearance change response to tenofovir treatment in HIV infection,6
Toenail selenium levels,30
Tonometry,11
Tonsillectomy,62
Tooth agenesis,5
Total bilirubin levels,20
Total bilirubin levels in HIV-1 infection,22
Total body bone mineral density,36
Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes,20
Total cholesterol levels,190
Total cholesterol levels in HDL,7
Total cholesterol levels in LDL,7
Total cholesterol levels in large LDL,5
Total cholesterol levels in medium LDL,5
Total cholesterol levels in small LDL,7
Total hippocampal volume,17
Total ventricular volume,8
Total ventricular volume (Alzheimer's disease interaction),12
Tourette syndrome,10
Tourette's syndrome or obsessive-compulsive disorder,40
Treatment response for severe sepsis,8
Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes,14
Triglyceride levels,104
Triglycerides,184
Triglycerides-Blood Pressure (TG-BP),6
Triptolide cytotoxicity,12
Tuberculosis,72
Tuberculosis (SNP x SNP interaction),24
Tumor biomarkers,8
Two-hour glucose challenge,5
Type 1 diabetes,91
Type 1 diabetes and autoimmune thyroid diseases,21
Type 1 diabetes autoantibodies in high risk HLA genotype individuals (time to event),10
Type 1 diabetes in high risk HLA genotype individuals (time to event),9
Type 1 diabetes nephropathy,8
Type 2 diabetes,397
"Type 2 diabetes (SNP x SNP interaction, 1df)",8
"Type 2 diabetes (SNP x SNP interaction, 2df)",20
Type 2 diabetes (age of onset),56
Type 2 diabetes (dietary heme iron intake interaction),6
Type 2 diabetes and other traits,9
Type 2 diabetes nephropathy,13
Type 2 diabetes nephropathy including microalbuminuria,6
Ulcerative colitis,456
Ulna and radius bone mineral density,7
Upper eyelid morphology,14
Upper eyelid sagging severity,11
Urate levels,74
Urate levels (BMI interaction),33
Urate levels in lean individuals,38
Urate levels in obese individuals,47
Urate levels in overweight individuals,43
Uric acid levels,31
Urinary albumin excretion,63
Urinary albumin excretion (no hypertensive medication),28
Urinary albumin-to-creatinine ratio,15
Urinary albumin-to-creatinine ratio in non-diabetics,22
Urinary bladder cancer,10
Urinary magnesium-to-creatinine ratio,6
Urinary metabolite concentrations in chronic kidney disease,13
Urinary metabolite ratios in chronic kidney disease,5
Urinary metabolites,18
Urinary metabolites (H-NMR features),10
Uterine fibroid number (single vs multiple),15
Uterine fibroid size (maximum dimension),10
Uterine fibroid size (maximum volume),8
Uterine fibroids,50
Vascular brain injury,5
Vascular endothelial growth factor levels,16
Vein graft stenosis in coronary artery bypass grafting,7
Venous thromboembolism,20
Venous thromboembolism adjusted for sickle cell variant rs77121243-T,86
Verbal declarative memory,57
Vertical cup-disc ratio,38
Very long-chain saturated fatty acid levels (fatty acid 20:0),30
Very long-chain saturated fatty acid levels (fatty acid 22:0),10
Vestibular neuritis,5
Vigorous physical activity,8
Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia,5
Virologic severity in Herpes simplex virus type 2 infection,11
Visceral adipose tissue,5
Visceral adipose tissue adjusted for BMI,55
Visceral adipose tissue/subcutaneous adipose tissue ratio,58
Visceral fat,46
Vitamin B levels in ischemic stroke,8
Vitamin B12 levels,6
Vitamin D levels,28
Vitamin D levels (dietary vitamin D intake interaction),6
Vitamin E levels,5
Vitiligo,121
Vogt-Koyanagi-Harada syndrome,9
Waist Circumference - Triglycerides (WC-TG),7
Waist circumference,75
Waist circumference adjusted for BMI (adjusted for smoking behaviour),81
Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction),87
Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction),79
Waist circumference adjusted for BMI in active individuals,85
Waist circumference adjusted for BMI in inactive individuals,8
Waist circumference adjusted for BMI in non-smokers,69
Waist circumference adjusted for BMI in smokers,12
Waist circumference adjusted for body mass index,128
Waist-hip ratio,58
Waist-to-hip circumference ratio (dietary energy interaction),5
Waist-to-hip circumference ratio (ever vs never smoking interaction),5
Waist-to-hip circumference ratio (smoking years interaction),5
Waist-to-hip ratio adjusted for BMI,367
Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour),68
Waist-to-hip ratio adjusted for BMI (age <50),153
Waist-to-hip ratio adjusted for BMI (age >50),250
Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction),56
Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction),32
Waist-to-hip ratio adjusted for BMI in active individuals,46
Waist-to-hip ratio adjusted for BMI in inactive individuals,8
Waist-to-hip ratio adjusted for BMI in non-smokers,32
Waist-to-hip ratio adjusted for BMI x sex interaction,24
Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test),419
Waist-to-hip ratio adjusted for body mass index,111
Warfarin maintenance dose,8
Wegener's granulomatosis,13
Weight,27
Weight loss (gastric bypass surgery),6
Western dietary pattern,23
White blood cell count,227
White blood cell count (basophil),95
White blood cell count (monocyte),7
White blood cell types,20
White matter growth,8
White matter hyperintensities in ischemic stroke,7
White matter hyperintensity burden,27
White matter integrity,10
White matter integrity (bipolar disorder risk interaction),8
White matter lesion progression,9
White matter lesion progression (adjusted for white matter lesion burden at baseline),6
Whole-brain volume (Alzheimer's disease interaction),5
Worry too long after an embarrassing experience,21
Yeast infection,5
Yu-Zhi constitution type in type 2 diabetes,5
Zinc levels,40
antipsychotic drug dosage in schizophrenia or schizoaffective disorder,7
circulating leptin levels,6
circulating leptin levels adjusted for BMI,5
facial morphology traits (multivariate analysis),5
middle facial morphology traits (quantitative measurement),5
nicotine metabolite ratio in current smokers,10
vWF and FVIII levels,10
